- Home
- NMS vs ACRV Comparison
NMS vs ACRV Comparison
Compare NMS & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMS | ACRV |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 74.0M |
| IPO Year | 2014 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NMS | ACRV |
|---|---|---|
| Price | $10.21 | $1.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 25.2K | ★ 216.5K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.48 | $1.27 |
| 52 Week High | $12.50 | $3.56 |
Technical Indicators
Market Signals| Indicator | NMS | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 41.59 |
| Support Level | $9.48 | $1.63 |
| Resistance Level | $12.48 | $2.21 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 77.52 | 22.73 |
Price Performance
Historical ComparisonAbout NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The company has Single operating segment.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.